Francesca Palandri/LinkedIn
Aug 17, 2026, 16:22
Francesca Palandri: Why Is Ruxolitinib Response So Heterogeneous in Myelofibrosis?
Francesca Palandri, Hematologist at IRCCS Sant’Orsola Polyclinic – Bologna University Hospital, shared on LinkedIn about a recent article she and Filippo Branzanti co-authored, published in Clinical Lymphoma Myeloma and Leukemia, adding:
”Why is ruxolitinib response so heterogeneous in myelofibrosis?
Our SOHO State of the Art review covers:
- Cytopenic vs. proliferative phenotype
- Dose intensity (the 1 modifiable factor)
- HMR mutations, RAS/CBL, cytogenetics
- Dynamic models RR6, iRR6, STR-PM
Moving from static baseline prognostication to response-driven precision medicine.”
Title: SOHO State of the Art Updates and Next Questions | Predictive Markers for Ruxolitinib in Myelofibrosis
Authors: Francesca Palandri, Filippo Branzanti
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 17, 2026, 17:03Ahmad Hazri Mohamed Aris: Strengthening Hemophilia Care in Fiji
-
Aug 17, 2026, 16:56Suspicion-Based Screening for Occult Malignancy in Lower Extremity Venous Thrombosis – JTH
-
Aug 17, 2026, 16:51Kathaleen Schnur: Celebrating The Bleeding Disorders Community
-
Aug 17, 2026, 16:45Eugenio Caradonna: Can Light Replace Chemicals in PRP Activation?
-
Aug 17, 2026, 16:30Jeff Sternlicht: We Don’t Measure Lp(a) Because We Have a Drug
-
Aug 17, 2026, 15:22Antoine Francis: The Hidden Power of Albumin
-
Aug 17, 2026, 15:13Gabriela A.: New FDA Approval Advances the Future of Dried Plasma
-
Aug 17, 2026, 15:01Alan Dursun: When Haemophilia Care Becomes a Reality
-
Aug 17, 2026, 14:58Registrations are Still Open for the EHC Health Economics Course 2026